Nature Communications (Apr 2018)
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
- Olli Dufva,
- Matti Kankainen,
- Tiina Kelkka,
- Nodoka Sekiguchi,
- Shady Adnan Awad,
- Samuli Eldfors,
- Bhagwan Yadav,
- Heikki Kuusanmäki,
- Disha Malani,
- Emma I Andersson,
- Paavo Pietarinen,
- Leena Saikko,
- Panu E. Kovanen,
- Teija Ojala,
- Dean A. Lee,
- Thomas P. Loughran,
- Hideyuki Nakazawa,
- Junji Suzumiya,
- Ritsuro Suzuki,
- Young Hyeh Ko,
- Won Seog Kim,
- Shih-Sung Chuang,
- Tero Aittokallio,
- Wing C. Chan,
- Koichi Ohshima,
- Fumihiro Ishida,
- Satu Mustjoki
Affiliations
- Olli Dufva
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Matti Kankainen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Tiina Kelkka
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Nodoka Sekiguchi
- Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine
- Shady Adnan Awad
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Samuli Eldfors
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Bhagwan Yadav
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Heikki Kuusanmäki
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Disha Malani
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Emma I Andersson
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Paavo Pietarinen
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- Leena Saikko
- Department of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University Hospital
- Panu E. Kovanen
- Department of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University Hospital
- Teija Ojala
- Pharmacology, Faculty of Medicine, University of Helsinki
- Dean A. Lee
- Nationwide Children’s Hospital, Division of Hematology, Oncology, and BMT
- Thomas P. Loughran
- Department of Medicine, University of Virginia
- Hideyuki Nakazawa
- Division of Hematology, Internal Medicine, Shinshu University School of Medicine
- Junji Suzumiya
- Department of Oncology/Hematology, Shimane University Hospital
- Ritsuro Suzuki
- Department of Oncology/Hematology, Shimane University Hospital
- Young Hyeh Ko
- Department of Pathology, Samsung Medical Center
- Won Seog Kim
- Sungkyunkwan University School of Medicine, Samsung Medical Center
- Shih-Sung Chuang
- Department of Pathology, Chi-Mei Medical Center
- Tero Aittokallio
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Wing C. Chan
- Department of Pathology, City of Hope National Medical Center
- Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine
- Fumihiro Ishida
- Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine
- Satu Mustjoki
- Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
- DOI
- https://doi.org/10.1038/s41467-018-03987-2
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic targets.
